Trials / Unknown
UnknownNCT06132698
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
Efficacy and Safety of Immune Checkpoint (PD-1) Inhibitor Combined With Pemetrexed Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with NSCLC associated with leptomeningeal metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab, pemetrexed | Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2024-11-30
- Completion
- 2025-11-30
- First posted
- 2023-11-15
- Last updated
- 2023-11-24
Source: ClinicalTrials.gov record NCT06132698. Inclusion in this directory is not an endorsement.